Table 3.
Risk factors for relapse within 12-month follow-up. Univariate analysis.
| N = 96 | No relapse (n = 74) | Relapse (n = 22) | p c,d |
|---|---|---|---|
| Female (%) | 30 (40) | 7 (32) | 0.487 |
| Median (IQR) age (years) | 51.0 (41.0–58.0) | 44.5 (37.5–60.8) | 0.210 |
| Median (IQR) disease duration (years) | 13.0 (9.0–21.0) | 7.5 (1.8–15.3) | 0.015 |
| Median (IQR) time from last relapse (months) | 25.0 (7.3–67) | 22.0 (12.0–33.0) | 0.964 |
| Montreal classificationa (%): E1/E2/E3 | 10/34/29 (14/47/39) | 4/11/7 (18/50/32) | 0.763 |
| Active smoking (%) | 7 (9) | 2 (5) | 0.827 |
| Primary sclerosing cholangitis (%) | 8 (11) | 0 | 0.194 |
| Median (IQR) C-reactive protein (mg/l) | 6 (9) | 15 (25) | 0.382 |
| Median (IQR) hemoglobin (g/dl) | 14.2 (13.1–15.3) | 13.6 (12.7–15.3) | 0.410 |
| Median (IQR) WBC (109/l) | 6.1 (4.9–7.9) | 6.1 (5.4–8.5) | 0.455 |
| Median (IQR) platelets (109/l) | 255.0 (202.0–295.0) | 246.5 (210.3–284.0) | 1 |
| Geboes’ score ≥ 2B.1(%) | 14 (19) | 11 (50) | 0.004 |
| Geboes’ score ≥ 3.1(%) | 12 (16) | 10 (46) | 0.004 |
| Basal plasmacytosis (%) | 6 (8%) | 4 (18%) | 0.236 |
| 5-ASA/immunosuppressantsb/anti-TNF | 50 (67) | 15(68) | 0.894 |
| Immunosuppressantsb | 16 (21) | 4 (18) | 1 |
| Anti-TNF | 24 (32) | 8 (36) | 0.702 |
a
UC extension according to Montréal classification (proctitis (E1), left-sided colitis (E2) extensive colitis (E3)). bImmunosuppressants, azathioprine, 6-mercaptopurine, tacrolimus. cp: calculated by χ2 test for qualitative variables. dp: calculated by Mann–Whitney U test for quantitative variables.
IRQ: interquartile range; 5-ASA: 5-aminosalicylates; Anti-TNF: anti-tumor necrosis factor; WBC: white blood cells.